Brief: Refile-Zydus Lifesciences Says Receipt Of Warning Letter From USFDA For Baddi Facility
BRIEF-Refile-Zydus Lifesciences Says Receipt Of Warning Letter From USFDA For Baddi Facility June 3 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS LIFESCIENCES - RECEIPT OF WARNING LETTER FROM USFDA FOR BADDI FACILITY
ZYDUS LIFESCIENCES - BELIEVE THAT SAID WARNING LETTER WILL NOT IMPACT CURRENT OPERATIONS, SUPPLIES FROM BADDI SITE
ZYDUS LIFESCIENCES - TECHNICAL OBSERVATIONS REGARDING THE USE OF PURIFIED TALC
ZYDUS LIFESCIENCES - PURIFIED TALC THAT DID NOT MEET CURRENT UNITED STATES PHARMACOPEIA REQUIREMENTS
Further company coverage: ZYDU.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zydus Lifesciences
See all newsIndia's Zydus Lifesciences posts lower profit as expenses outpace revenue growth
Brief: Zydus Lifesciences Q2 Consol Net Profit 9.26 Billion Rupees
Brief: Zydus Lifesciences Says Zylidac Bio And Prolific Machines Partner
Brief: Zydus Lifesciences Receives U.S. FDA Approval For Estradiol And Levonorgestrel Transdermal System
Brief: Zydus Lifesciences Says Zydus Sunshine Lifesciences Signs Agreement To Establish A Pharmaceutical Manufacturing Facility In Sri Lanka